Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone

Holst, T. von; Lang, Eva; Winkler, Ulrich; Keil, Dieter

doi:10.1016/s0378-5122(02)00203-7

Cited by 24 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to many other studies investigating bleeding pattern, the CHOICE trial provided data for up to only 6 months of treatment. However, the available literature on the pattern of bleeding over time in postmenopausal women using ccEPT indicates that bleeding is more common in the initial months of use 17,23,29 and that it gradually declines with duration of therapy 17,30,31 . The data from the E2/NETA 0.1 group show the same pattern, so it is expected that, with continued use beyond 6 months, the rate of amenorrhea would improve further.…”

Section: Discussionmentioning

confidence: 99%

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

et al. 2008

View full text Add to dashboard Cite

show abstract

“…4,5 Clinical comparison studies of these compounds have focused mainly on mode of delivery, and outcomes have generally been restricted to the relief of menopausal symptoms and the occurrence of vaginal bleeding. [6][7][8] Nearly all comparisons have evaluated the most commonly used estrogens, CEE and micronized estradiol. Esterified estrogens (EEs) have received less attention.…”

Section: Linical Trial Evidence Frommentioning

confidence: 99%

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis

Smith¹,

Heckbert²,

Lemaître³

2005

ACC Current Journal Review

View full text Add to dashboard Cite

“…Bleeding rates during treatment with this lower dose regimen are reported to be low and a direct comparison of 1 mg E 2 plus 0.5 mg NETA with a conventional regimen of 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate confirmed this more favourable bleeding profile with the former regimen. [16][17][18][19] Higher dose estrogen-progestogen combinations compare unfavourably with tibolone with respect to bleeding and breast-related adverse events (AEs), whereas lower dose regimens have not been compared with tibolone. 8,9,[20][21][22] Therefore, the aim of the present study was to compare the occurrence of vaginal bleeding, efficacy and tolerability of 2.5 mg tibolone with 1 mg E 2 and 0.5 mg NETA.…”

Section: Introductionmentioning

confidence: 99%

Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability

Hammar

Weijer

et al. 2007

BJOG

View full text Add to dashboard Cite

ObjectivesThe primary objective was to compare the vaginal bleeding pattern during administration of tibolone and low-dose continuous combined estradiol plus norethisterone acetate (E 2 / NETA). The secondary objectives were efficacy on vasomotor symptoms and vaginal atrophy.Design A randomised, double-blind, double-dummy, group comparative intervention trial.Setting Multicentre study executed in 32 centres in 7 European countries.Sample Five hundred and seventy-two healthy symptomatic postmenopausal women, aged 45-65 years.Methods Participants were randomised to receive 2.5 mg tibolone or 1 mg 17b estradiol plus 0.5 mg norethisterone acetate (E 2 / NETA) daily for 48 weeks.Main outcome measures Prevalence of vaginal bleeding, hot flushes and adverse events.Results The incidence of bleeding was significantly lower in the tibolone group during the first 3 months of treatment (18.3 versus 33.1%; P < 0.001) when compared with the E 2 /NETA group. This effect on the bleeding pattern was sustained throughout the study, although reaching statistical significance again only in 7-9 months of treatment (11 versus 19%; P < 0.05). In both treatment groups, vasomotor symptoms and vaginal atrophy were significantly reduced to a similar extent when compared with baseline. The prevalence of breast pain/tenderness was significantly lower with tibolone compared with E 2 /NETA (3.2 versus 9.8%; P < 0.001).Conclusion Tibolone reduces menopausal symptoms to a similar extent as conventional low-dose continuous combined hormone therapy but causes significant less vaginal bleeding in the first 3 months of treatment. This constitutes an important argument for woman adherence to therapy.

show abstract

Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone

Cited by 24 publications

References 16 publications

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis

Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability

Contact Info

Product

Resources

About